• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region.

作者信息

Becchetti Antonella Giorgia, Martini Anna, Scroccaro Giovanna, Joppi Roberta

机构信息

Territorial Pharmaceutical Assistance Unit, Azienda ULSS 9 Scaligera, Verona, Italy.

Department Diagnostic and Public Health, University of Verona, Verona, Italy.

出版信息

Front Pharmacol. 2024 Aug 6;15:1406351. doi: 10.3389/fphar.2024.1406351. eCollection 2024.

DOI:10.3389/fphar.2024.1406351
PMID:39166105
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11333330/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7fc/11333330/534221620910/fphar-15-1406351-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7fc/11333330/828497caff21/fphar-15-1406351-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7fc/11333330/534221620910/fphar-15-1406351-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7fc/11333330/828497caff21/fphar-15-1406351-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7fc/11333330/534221620910/fphar-15-1406351-g002.jpg

相似文献

1
History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region.曲妥珠单抗的历史：威尼托地区卫生技术重新评估与自然撤资的案例研究
Front Pharmacol. 2024 Aug 6;15:1406351. doi: 10.3389/fphar.2024.1406351. eCollection 2024.
2
Sustainability of healthcare systems in Asia: exploring the roles of horizon scanning and reassessment in the health technology assessment landscape.亚洲医疗体系的可持续性：探索在卫生技术评估领域中进行前瞻性扫描和重新评估的作用。
Int J Technol Assess Health Care. 2020 Jun;36(3):262-269. doi: 10.1017/S0266462320000252. Epub 2020 May 11.
3
Disinvestment Activities and Candidates in the Health Technology Assessment Community: An Online Survey.卫生技术评估界的撤资活动和候选人：一项在线调查。
Int J Technol Assess Health Care. 2019 Jan;35(3):189-194. doi: 10.1017/S0266462319000229. Epub 2019 Apr 22.
4
Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications.卫生技术评估机构的观点：为处方药的卫生技术再评估修改定性获益风险框架提供信息。
Int J Technol Assess Health Care. 2019;35(5):384-392. doi: 10.1017/S026646231900062X. Epub 2019 Sep 16.
5
Knowledge translation and health technology reassessment: identifying synergy.知识转化与卫生技术重新评估：识别协同作用。
BMC Health Serv Res. 2018 Aug 30;18(1):674. doi: 10.1186/s12913-018-3494-y.
6
Disinvestment in healthcare: a scoping review of systematic reviews.医疗保健领域的撤资：系统评价的范围综述。
Int J Technol Assess Health Care. 2022 Jul 20;38(1):e69. doi: 10.1017/S0266462322000514.
7
A systematic review on current status of health technology reassessment: insights for South Korea.关于健康技术再评估现状的系统评价：对韩国的启示
Health Res Policy Syst. 2016 Nov 11;14(1):82. doi: 10.1186/s12961-016-0152-x.
8
Characteristics of knowledge translation theories, models and frameworks for health technology reassessment: expert perspectives through a qualitative exploration.卫生技术重新评估的知识转化理论、模型和框架的特征：通过定性探索得出的专家观点
BMC Health Serv Res. 2021 Apr 29;21(1):401. doi: 10.1186/s12913-021-06382-8.
9
Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.医疗保健领域的撤资：欧洲层面卫生技术评估机构及组织活动概述
BMC Health Serv Res. 2018 Mar 1;18(1):148. doi: 10.1186/s12913-018-2941-0.
10
Health technology reassessment of non-drug technologies: current practices.非药物技术的卫生技术重新评估：当前实践。
Int J Technol Assess Health Care. 2012 Jul;28(3):220-7. doi: 10.1017/S0266462312000438.

本文引用的文献

1
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.曲妥珠单抗 deruxtecan 对比曲妥珠单抗 emtansine 用于治疗 HER2 阳性转移性乳腺癌：DESTINY-Breast03 试验的长期生存分析。
Nat Med. 2024 Aug;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7. Epub 2024 Jun 2.
2
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.基于曲妥珠单抗的抗体药物偶联物的安全性概况：对欧洲药品不良反应数据库（EudraVigilance）中登记的真实世界数据的分析
Biomedicines. 2024 Apr 25;12(5):953. doi: 10.3390/biomedicines12050953.
3
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.
用于治疗乳腺癌的上市抗体药物偶联物（ADC）的研究进展
Front Pharmacol. 2024 Jan 30;14:1332539. doi: 10.3389/fphar.2023.1332539. eCollection 2023.
4
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.人乳腺癌中的低 HER2 和超低 HER2：定义新肿瘤亚型的努力。
Int J Mol Sci. 2023 Aug 14;24(16):12795. doi: 10.3390/ijms241612795.
5
Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.抗体药物偶联物在乳腺癌治疗中的应用：新兴药物、靶点及未来方向。
Int J Mol Sci. 2023 Jul 25;24(15):11903. doi: 10.3390/ijms241511903.
6
Mechanisms of Resistance to Antibody-Drug Conjugates.抗体药物偶联物耐药机制。
Int J Mol Sci. 2023 Jun 2;24(11):9674. doi: 10.3390/ijms24119674.
7
Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment.社论：卫生技术评估与结果研究时代的药物经济学，以优化资源利用、创新与投资。
Front Pharmacol. 2023 May 16;14:1210002. doi: 10.3389/fphar.2023.1210002. eCollection 2023.
8
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.HER2 低表达乳腺癌——来自正在进行的研究的诊断挑战和见解：播客。
Target Oncol. 2023 May;18(3):313-319. doi: 10.1007/s11523-023-00964-8. Epub 2023 May 3.
9
The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis.曲妥珠单抗-德鲁替康（T-DXd）在 HER2 表达型实体瘤中的疗效和安全性：一项单臂汇总分析。
Jpn J Clin Oncol. 2023 Jul 31;53(8):722-729. doi: 10.1093/jjco/hyad036.
10
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.与曲妥珠单抗恩美曲妥珠单抗和曲妥珠单抗德鲁昔康治疗HER2阳性/突变恶性肿瘤相关的高风险不良事件：一项基于FAERS数据库的药物警戒研究。
Expert Opin Drug Saf. 2023 Jul-Dec;22(8):685-696. doi: 10.1080/14740338.2023.2204228. Epub 2023 Apr 20.